Drug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that will see him work with the R&D team fronting the clinical development of the company’s lead candidate.
Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs.
He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as CMO.
During his career, Dr Saunders has held several roles for both pharma and biotech companies, including Genzyme – now part of Sanofi, Roche, and Eli Lilly.
Ian Ross, chairman of Redx Pharma, said: “Dr Saunders brings a wealth of relevant experience and expertise in the clinical development of oncology drugs, which will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004.”